Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 12/20 | 0.61 |
| ▸ | GRM5 | P41594 | 12/20 | 0.61 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892933 | 0.88 | GRM1 (0.44) | GRM1GRM5 | |
| SCHEMBL2893158 | 0.87 | GRM1 (0.69) | GRM1GRM5PDK4HTR6TNK2 | |
| SCHEMBL3794398 | 0.78 | GRM5 (0.57) | GRM1GRM5PDK4TNK2PDE10A | |
| SCHEMBL8613189 | 0.78 | GRM1 (0.62) | GRM1GRM5PDK4HTR6TNK2 | |
| SCHEMBL20217955 | 0.77 | GRM1 (0.56) | GRM1GRM5PDK4HTR6TNK2 | |
| SCHEMBL2885501 | 0.77 | GRM1 (0.69) | GRM1GRM5GPR119 | |
| SCHEMBL27007980 | 0.77 | GRM1 (0.61) | GRM1GRM5PDK4TNK2NAMPT | |
| SCHEMBL2239831 | 0.76 | NAMPT (0.66) | GRM1GRM5PDK4HTR6TNK2 | |
| SCHEMBL23505457 | 0.76 | GRM1 (0.55) | GRM1GRM5PDK4HTR6TNK2 | |
| SCHEMBL12975512 | 0.76 | GRM1 (0.65) | GRM1GRM5PDK4PDE10ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858800-B2 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191389-A1 | Biaryl derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1764362-A1 | BIARYL DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191389-A1 | Biaryl derivatives | GRM1, GRIN1, GRIN2B | GRM1 1/4885GRM5 26/4885PDK4 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.